文献速递细菌感染、耐药与抗菌药物

阿维巴坦对铜绿假单胞菌的PK/PD指数模型分析

A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.
PubMed 文献 · Clin Microbiol Infect · 2018-10-28

该研究利用基于体外时间杀菌数据构建的半机制PK/PD模型,模拟头孢他啶-阿维巴坦对铜绿假单胞菌的杀菌效果。结果显示阿维巴坦的最佳PD指数为fT>1 mg/L,每8小时给药是能实现2-log杀菌的最长间隔,且所需暴露量取决于菌株对头孢他啶的敏感性。

要点

  • 阿维巴坦与头孢他啶联用对MDR铜绿假单胞菌的活性与fT>CT相关。
  • 设定阿维巴坦阈值浓度1 mg/L,每8小时给药可实现至少2-log杀菌。
  • 频繁给药可提高疗效并降低阿维巴坦日剂量。

核心结论

  • 阿维巴坦联合头孢他啶对多重耐药铜绿假单胞菌的活性与fT>CT相关。

研究设计与样本

  • 利用体外时间杀菌数据构建的半机制PK/PD数学模型,模拟人类暴露下不同阿维巴坦给药方案联合固定头孢他啶方案(2或8g q8h,2小时输注)的细菌反应。

主要发现

  • 频繁给药与更高疗效相关,并可降低阿维巴坦日剂量。
  • 最佳PD指数为fT>1 mg/L阿维巴坦,q8h是能实现2-log杀菌的最长给药间隔,达标时间为41-87%(即8小时间隔内3.3至7.0小时)。
  • 模拟中实现2-log杀菌所需的阿维巴坦暴露量取决于菌株对头孢他啶的敏感性。

关键数值与推荐

  • 阿维巴坦阈值浓度设为1 mg/L,在模拟人类头孢他啶暴露下,临床剂量500 mg q8h(2小时输注)可实现至少2-log杀菌,取决于单用头孢他啶的MIC。

临床怎么用

  • 对于MDR铜绿假单胞菌感染,可考虑阿维巴坦500 mg q8h(2小时输注)联合头孢他啶方案,但需结合头孢他啶MIC评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the present work was to use a semi-mechanistic pharmacokinetic-pharmacodynamic (PK/PD) model developed from in vitro time-kill measurements with P. aeruginosa to compare different pharmacodynamic indices derived from simulated human avibactam exposures, with respect to their degree of correlation with the modelled bacterial responses. METHODS: A mathematical model of the effect of ceftazidime-avibactam on the growth dynamics of P. aeruginosa was used to simulate bacterial responses to modelled human exposures from fractionated avibactam dosing regimens with a fixed ceftazidime dosing regimen (2 or 8 g q8h as a 2-h infusion). The relatedness of the 24-h change in bacterial density and avibactam exposure parameters was evaluated to determine exposure parameter that closely correlated with bacterial growth/killing responses. RESULTS: Frequent dosing was associated with higher efficacy, resulting in a reduction of avibactam daily dose. The best-fit PD index of avibactam determined from the simulation was fT > CT of 1 mg/L avibactam and q8h was the longest dosing interval able to achieve 2-log kill: 41-87% (3.3 h to 7.0 h out of 8-h interval, respectively). The avibactam exposure magnitude required to achieve a 2-log kill in the simulations was dependent on the susceptibility of the bacterial isolate to ceftazidime. CONCLUSIONS: Avibactam activity in combination with ceftazidime against multidrug resistant P. aeruginosa correlated with fT > CT. Setting a threshold avibactam concentration to 1 mg/L, superimposed over a simulated human-like exposure of ceftazidime, achieved at least 2-log kill for the clinical dose of 500 mg q8h avibactam as a 2-h infusion, depending on the minimum inhibitory concentration of ceftazidime alone.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Sy SKB, Zhuang L, Xia H, et al. A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa. Clin Microbiol Infect. 2018. PMID: 30394361. doi:10.1016/j.cmi.2018.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。